About Aridis Pharma
Aridis Pharma is a company based in San Jose (United States) founded in 2005 by Vu Truong. Aridis Pharma has raised $42.11 million across 14 funding rounds from investors including HHS, Cystic Fibrosis Foundation and SBIR. Aridis Pharma offers products and services including AR-301, AR-501, AR-320, and AR-701. Aridis Pharma operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Insmed, among others.
- Headquarter San Jose, United States
- Founders Vu Truong
- Stage Public
- SectorsHealthcare
- Website aridispharma.com
- Social LinkedIn X
- Legal Name Aridis Pharmaceuticals Inc.
- Annual Revenue$3.09 M (USD)101.37as on Dec 31, 2022
- Net Profit-$30.37 M (USD)28.02as on Dec 31, 2022
- EBITDA-$29.51 M (USD)30.21as on Dec 31, 2022
- Total Equity Funding$42.11M (USD)
in 14 rounds
- Latest Funding Round$4.85M (USD), Post-IPO
Dec 2022
- InvestorsHHS
& 3 more
Products & Services of Aridis Pharma
Aridis Pharma offers a comprehensive portfolio of products and services, including AR-301, AR-501, AR-320, and AR-701.
Targets S. aureus alpha-toxin for pneumonia treatment
Inhalable therapy to starve bacteria in cystic fibrosis
Prevents S. aureus infections in ventilated patients
Neutralizes SARS-CoV-2 variants for COVID-19 treatment
Funding Insights of Aridis Pharma
Aridis Pharma has successfully raised a total of $42.11M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.85 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.11M
- Total Rounds 14
- Last Round Post-IPO — $4.85M
- First Round $2.92M
(Dec 2006)
- Investors Count 4
Latest 10 of 14 funding rounds of Aridis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $4.85M | Post-IPO | – | – | – |
| Oct 2020 | $8.5M | Post-IPO | – | – | – |
| Jan 2017 | – | Grant | – | – | |
| Dec 2016 | $13.64M | Series B | – | – | – |
| Aug 2016 | $15.22M | Series B | – | – | – |
| Nov 2015 | $3M | Series A | – | – | – |
| Oct 2015 | – | Grant | – | – | |
| Sep 2014 | $6.75M | Series A | – | – | – |
| Jul 2014 | $3.5M | Series A | – | – | – |
| Jun 2014 | $566,303 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Aridis Pharma
Aridis Pharma has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Cystic Fibrosis Foundation and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Administers health care and support for military personnel and operations. | – | health.mil | Falls Church, United States |
Investor details for Aridis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aridis Pharma
13 people are tracked at Aridis Pharma (4 in leadership, 3 in board & advisors, 6 in team).
| Name | Role | Group |
|---|---|---|
Vu Truong | Founder & CEO | Leadership |
Elizabeth Leininger | VP of Regulatory Affairs | Leadership |
Vu L. Truong | Founder & CEO | Leadership |
Hasan Jafri | Chief Medical Officer | Leadership |
Eric J. Patzer | Founder & Chairman | Board & advisors |
John F. Hamilton | Director | Board & advisors |
Susan R. Windham-Bannister | Director | Board & advisors |
Jeffrey J. Fessler | Acting General Counsel | Team |
Fred Kurland | Senior Financial Consultant | Team |
Hearne | Associate Scientist /lab Manager | Team |
Charles Nguyen | Research Intern | Team |
Stefanie Matsuoka-Luning | Project / Program Manager | Team |
Padma J. | Associate Scientist | Team |
Complete people profiles for Aridis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aridis Pharma
Aridis Pharma is a publicly listed company on the OTC with ticker symbol ARDS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Aug 2018
- Listed onNASDAQ: ARDS
- Listed entityAridis Pharmaceuticals Inc.
- Exchange sectorHealth technology
- ISINUS0403341045
- Share price$0.00 · 2026-10-08
- Market capitalisation$4,457.00
- Volume (last session)2,000
Financials of Aridis Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $3.1M | -$30.4M | -$29.5M |
| 2021 | $1.5M | -$42.2M | -$42.3M |
| 2020 | $1.0M | -$22.3M | -$22.1M |
Detailed financial statements for Aridis Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Aridis Pharma
4 dated milestones of Aridis Pharma across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Aridis Pharma is founded.
- Funding First funding round of $2.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.8M.
Competitors of Aridis Pharma
Aridis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Insmed, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| zailaboratory.com | 2013 | Shanghai, China | $160M | – | Antibody-based therapies for cancers and inflammatory diseases are developed. | |
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. |
Detailed competitors of Aridis Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aridis Pharma
The website of Aridis Pharma (aridispharma.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 13.4% vs previous month
Websites whose visitors overlap most with Aridis Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| crypticstudios.com | 100% | 31.5K | #966,963 | View details | |
| audiblemagic.com | 80% | 16.8K | #1,504,808 | View details |
Latest news on Aridis Pharma
Complete news archive for Aridis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Aridis Pharma
10 companies that operate in the same segment as Aridis Pharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aridis Pharma
Aridis Pharma was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Aridis Pharma is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Vu Truong is the current CEO of Aridis Pharma. They have also founded this company.
Aridis Pharma is a funded company, having raised a total of $42.11M across 14 funding rounds to date. The company's 1st funding round was a Grant of $566.3K, raised on Dec 2006.
Annual revenue of Aridis Pharma is $3.09M as on Dec 31, 2022.
Provider of human monoclonal antibodies against infectious diseases. The companys lead human antibodies candidates are against hospital-acquired pneumonia, ventilator-associated pneumonia, and cystic fibrosis. The companys products target infectious diseases, including nosocomial infections, cystic fibrosis, and severe wound infections. In addition, it offers mAb discovery technology platform that enables the recovery of rare, naturally occurring protective antibodies generated by the human immune system.
Aridis Pharma's top competitors include argenx, Zai Lab and Kodiak Sciences.
Aridis Pharma offers AR-301, AR-501, AR-320, and AR-701.
Yes, Aridis Pharma is publicly traded on OTC under the ticker symbol ARDS.
Aridis Pharma has 4 investors. Key investors include HHS, Cystic Fibrosis Foundation, SBIR, and Military Health.
Aridis Pharma operates through Aridis Pharmaceuticals, Inc..